Biomarin Pharmaceutical Net Worth
Biomarin Pharmaceutical Net Worth Breakdown | BMRN |
Biomarin Pharmaceutical Net Worth Analysis
Biomarin Pharmaceutical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biomarin Pharmaceutical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biomarin Pharmaceutical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biomarin Pharmaceutical's net worth analysis. One common approach is to calculate Biomarin Pharmaceutical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biomarin Pharmaceutical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biomarin Pharmaceutical's net worth. This approach calculates the present value of Biomarin Pharmaceutical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biomarin Pharmaceutical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biomarin Pharmaceutical's net worth. This involves comparing Biomarin Pharmaceutical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biomarin Pharmaceutical's net worth relative to its peers.
Enterprise Value |
|
To determine if Biomarin Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomarin Pharmaceutical's net worth research are outlined below:
| Biomarin Pharmaceutical is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Insider Sell Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc |
Biomarin Pharmaceutical Quarterly Good Will |
|
Biomarin Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomarin Pharmaceutical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomarin Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Biomarin Pharmaceutical Target Price Consensus
Biomarin target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Biomarin Pharmaceutical's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 26 | Strong Buy |
Most Biomarin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Biomarin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Biomarin Pharmaceutical, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBiomarin Pharmaceutical Target Price Projection
Biomarin Pharmaceutical's current and average target prices are 68.81 and 97.66, respectively. The current price of Biomarin Pharmaceutical is the price at which Biomarin Pharmaceutical is currently trading. On the other hand, Biomarin Pharmaceutical's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Biomarin Pharmaceutical Market Quote on 27th of February 2025
Target Price
Analyst Consensus On Biomarin Pharmaceutical Target Price
Know Biomarin Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Biomarin Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biomarin Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 3.3 M | Bank Of New York Mellon Corp | 2024-12-31 | 2.4 M | Northern Trust Corp | 2024-12-31 | 1.7 M | Deutsche Bank Ag | 2024-12-31 | 1.7 M | Ubs Group Ag | 2024-12-31 | 1.5 M | Venbio Select Advisor Llc | 2024-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.3 M | Aqr Capital Management Llc | 2024-12-31 | 1.3 M | Blackrock Inc | 2024-12-31 | 23.5 M | Vanguard Group Inc | 2024-12-31 | 19.4 M |
Follow Biomarin Pharmaceutical's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.58 B.Market Cap |
|
Project Biomarin Pharmaceutical's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.08 | 0.08 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.08 | 0.08 |
When accessing Biomarin Pharmaceutical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biomarin Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomarin Pharmaceutical's profitability and make more informed investment decisions.
Evaluate Biomarin Pharmaceutical's management efficiency
Biomarin Pharmaceutical has return on total asset (ROA) of 0.0515 % which means that it generated a profit of $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0805 %, meaning that it created $0.0805 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.08. At this time, Biomarin Pharmaceutical's Net Tangible Assets are very stable compared to the past year. As of the 27th of February 2025, Return On Tangible Assets is likely to grow to 0.07, while Intangible Assets are likely to drop about 245.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 29.77 | 31.26 | |
| Tangible Book Value Per Share | 27.40 | 28.77 | |
| Enterprise Value Over EBITDA | 25.08 | 26.33 | |
| Price Book Value Ratio | 2.21 | 3.91 | |
| Enterprise Value Multiple | 25.08 | 26.33 | |
| Price Fair Value | 2.21 | 3.91 | |
| Enterprise Value | 15 B | 9.8 B |
The strategic initiatives led by Biomarin Pharmaceutical's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 4.4123 | Revenue | Quarterly Revenue Growth 0.156 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomarin Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomarin Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomarin Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biomarin Pharmaceutical Corporate Filings
F3 | 26th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 25th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 24th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 19th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Biomarin Pharmaceutical Earnings Estimation Breakdown
The calculation of Biomarin Pharmaceutical's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Biomarin Pharmaceutical is estimated to be 0.6517 with the future projection ranging from a low of 0.71 to a high of 1.16. Please be aware that this consensus of annual earnings estimates for Biomarin Pharmaceutical is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.71 Lowest | Expected EPS | 1.16 Highest |
Biomarin Pharmaceutical Earnings Projection Consensus
Suppose the current estimates of Biomarin Pharmaceutical's value are higher than the current market price of the Biomarin Pharmaceutical stock. In this case, investors may conclude that Biomarin Pharmaceutical is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Biomarin Pharmaceutical's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 29 | 70.04% | 0.92 | 0.6517 | 2.13 |
Biomarin Pharmaceutical Earnings per Share Projection vs Actual
Actual Earning per Share of Biomarin Pharmaceutical refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Biomarin Pharmaceutical predict the company's earnings will be in the future. The higher the earnings per share of Biomarin Pharmaceutical, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Biomarin Pharmaceutical Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Biomarin Pharmaceutical, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Biomarin Pharmaceutical should always be considered in relation to other companies to make a more educated investment decision.Biomarin Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Biomarin Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-20 | 2024-12-31 | 0.7386 | 0.92 | 0.1814 | 24 | ||
2024-10-29 | 2024-09-30 | 0.52 | 0.55 | 0.03 | 5 | ||
2024-08-05 | 2024-06-30 | 0.35 | 0.56 | 0.21 | 60 | ||
2024-04-24 | 2024-03-31 | 0.35 | 0.46 | 0.11 | 31 | ||
2024-02-22 | 2023-12-31 | 0.23 | 0.18 | -0.05 | 21 | ||
2023-11-01 | 2023-09-30 | 0.23 | 0.21 | -0.02 | 8 | ||
2023-07-31 | 2023-06-30 | 0.23 | 0.29 | 0.06 | 26 | ||
2023-04-26 | 2023-03-31 | 0.18 | 0.27 | 0.09 | 50 | ||
2023-02-27 | 2022-12-31 | -0.07 | -0.0013 | 0.0687 | 98 | ||
2022-10-26 | 2022-09-30 | -0.01 | -0.04 | -0.03 | 300 | ||
2022-08-03 | 2022-06-30 | 0.11 | 0.15 | 0.04 | 36 | ||
2022-04-27 | 2022-03-31 | 0.17 | 0.18 | 0.01 | 5 | ||
2022-02-23 | 2021-12-31 | -0.32 | -0.32 | 0.0 | 0 | ||
2021-10-27 | 2021-09-30 | -0.25 | -0.2 | 0.05 | 20 | ||
2021-07-28 | 2021-06-30 | -0.11 | 0.07 | 0.18 | 163 | ||
2021-04-29 | 2021-03-31 | -0.07 | 0.09 | 0.16 | 228 | ||
2021-02-25 | 2020-12-31 | -0.19 | 0.12 | 0.31 | 163 | ||
2020-11-05 | 2020-09-30 | 1.24 | 4.01 | 2.77 | 223 | ||
2020-08-04 | 2020-06-30 | -0.1 | -0.02 | 0.08 | 80 | ||
2020-04-29 | 2020-03-31 | 0.05 | 0.44 | 0.39 | 780 | ||
2020-02-26 | 2019-12-31 | -0.06 | 0.08 | 0.14 | 233 | ||
2019-10-23 | 2019-09-30 | 0.06 | 0.3 | 0.24 | 400 | ||
2019-08-01 | 2019-06-30 | -0.11 | -0.21 | -0.1 | 90 | ||
2019-04-25 | 2019-03-31 | -0.19 | -0.32 | -0.13 | 68 | ||
2019-02-21 | 2018-12-31 | -0.25 | -0.02 | 0.23 | 92 | ||
2018-10-25 | 2018-09-30 | -0.22 | -0.07 | 0.15 | 68 | ||
2018-08-02 | 2018-06-30 | -0.17 | -0.21 | -0.04 | 23 | ||
2018-04-25 | 2018-03-31 | -0.17 | -0.25 | -0.08 | 47 | ||
2018-02-22 | 2017-12-31 | -0.23 | -0.4 | -0.17 | 73 | ||
2017-10-26 | 2017-09-30 | -0.14 | -0.07 | 0.07 | 50 | ||
2017-08-02 | 2017-06-30 | -0.21 | -0.21 | 0.0 | 0 | ||
2017-05-04 | 2017-03-31 | -0.29 | -0.09 | 0.2 | 68 | ||
2017-02-23 | 2016-12-31 | -0.38 | -0.53 | -0.15 | 39 | ||
2016-10-27 | 2016-09-30 | -0.39 | -0.26 | 0.13 | 33 | ||
2016-08-04 | 2016-06-30 | -0.52 | 1.08 | 1.6 | 307 | ||
2016-04-28 | 2016-03-31 | -0.84 | -0.53 | 0.31 | 36 | ||
2016-02-25 | 2015-12-31 | 0.99 | 0.39 | -0.6 | 60 | ||
2015-10-29 | 2015-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2015-08-03 | 2015-06-30 | -0.53 | -0.43 | 0.1 | 18 | ||
2015-04-30 | 2015-03-31 | -0.53 | -0.38 | 0.15 | 28 | ||
2015-02-25 | 2014-12-31 | -0.59 | -0.47 | 0.12 | 20 | ||
2014-10-23 | 2014-09-30 | -0.23 | -0.38 | -0.15 | 65 | ||
2014-07-30 | 2014-06-30 | -0.42 | -0.22 | 0.2 | 47 | ||
2014-05-01 | 2014-03-31 | -0.46 | -0.33 | 0.13 | 28 | ||
2014-02-26 | 2013-12-31 | -0.35 | -0.43 | -0.08 | 22 | ||
2013-10-24 | 2013-09-30 | -0.3 | -0.38 | -0.08 | 26 | ||
2013-07-25 | 2013-06-30 | -0.29 | -0.15 | 0.14 | 48 | ||
2013-04-25 | 2013-03-31 | -0.29 | -0.31 | -0.02 | 6 | ||
2013-02-21 | 2012-12-31 | -0.27 | -0.43 | -0.16 | 59 | ||
2012-10-25 | 2012-09-30 | -0.2 | -0.04 | 0.16 | 80 | ||
2012-08-01 | 2012-06-30 | -0.21 | -0.27 | -0.06 | 28 | ||
2012-04-26 | 2012-03-31 | -0.14 | -0.21 | -0.07 | 50 | ||
2012-02-16 | 2011-12-31 | -0.11 | -0.23 | -0.12 | 109 | ||
2011-10-27 | 2011-09-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2011-07-28 | 2011-06-30 | -0.11 | -0.05 | 0.06 | 54 | ||
2011-04-28 | 2011-03-31 | -0.1 | -0.04 | 0.06 | 60 | ||
2011-02-17 | 2010-12-31 | -0.02 | 0.01 | 0.03 | 150 | ||
2010-10-28 | 2010-09-30 | -0.01 | 1.68 | 1.69 | 16900 | ||
2010-08-02 | 2010-06-30 | 0.03 | -0.01 | -0.04 | 133 | ||
2010-02-23 | 2009-12-31 | 0.01 | 0.05 | 0.04 | 400 | ||
2009-10-28 | 2009-09-30 | 0.01 | 0.06 | 0.05 | 500 | ||
2009-07-30 | 2009-06-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2009-04-30 | 2009-03-31 | -0.12 | -0.13 | -0.01 | 8 | ||
2009-02-18 | 2008-12-31 | 0.26 | 0.21 | -0.05 | 19 | ||
2008-10-28 | 2008-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2008-08-05 | 2008-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
2008-04-29 | 2008-03-31 | -0.05 | 0.02 | 0.07 | 140 | ||
2008-02-26 | 2007-12-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2007-11-01 | 2007-09-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2007-08-07 | 2007-06-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2007-04-30 | 2007-03-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2007-02-20 | 2006-12-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2006-11-01 | 2006-09-30 | -0.13 | -0.08 | 0.05 | 38 | ||
2006-08-02 | 2006-06-30 | -0.11 | -0.02 | 0.09 | 81 | ||
2006-05-03 | 2006-03-31 | -0.21 | -0.13 | 0.08 | 38 | ||
2006-02-23 | 2005-12-31 | -0.22 | -0.2 | 0.02 | 9 | ||
2005-11-01 | 2005-09-30 | -0.28 | -0.21 | 0.07 | 25 | ||
2005-08-01 | 2005-06-30 | -0.35 | -0.33 | 0.02 | 5 | ||
2005-05-05 | 2005-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2005-02-23 | 2004-12-31 | -0.33 | -0.23 | 0.1 | 30 | ||
2004-11-03 | 2004-09-30 | -0.36 | -0.4 | -0.04 | 11 | ||
2004-08-09 | 2004-06-30 | -0.29 | -0.28 | 0.01 | 3 | ||
2004-05-04 | 2004-03-31 | -0.31 | -0.31 | 0.0 | 0 | ||
2004-02-03 | 2003-12-31 | -0.38 | -0.4 | -0.02 | 5 | ||
2003-11-04 | 2003-09-30 | -0.39 | -0.33 | 0.06 | 15 | ||
2003-08-05 | 2003-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2003-05-05 | 2003-03-31 | -0.28 | -0.35 | -0.07 | 25 | ||
2003-02-09 | 2002-12-31 | -0.35 | -0.36 | -0.01 | 2 | ||
2002-10-31 | 2002-09-30 | -0.31 | -0.32 | -0.01 | 3 | ||
2002-08-01 | 2002-06-30 | -0.29 | -0.27 | 0.02 | 6 | ||
2002-05-07 | 2002-03-31 | -0.33 | -0.51 | -0.18 | 54 | ||
2002-02-25 | 2001-12-31 | -0.3 | -0.34 | -0.04 | 13 | ||
2001-10-26 | 2001-09-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2001-07-27 | 2001-06-30 | -0.26 | -0.3 | -0.04 | 15 | ||
2001-04-27 | 2001-03-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2001-02-22 | 2000-12-31 | -0.33 | -0.28 | 0.05 | 15 | ||
2000-10-30 | 2000-09-30 | -0.29 | -0.23 | 0.06 | 20 | ||
2000-07-28 | 2000-06-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2000-04-28 | 2000-03-31 | -0.26 | -0.34 | -0.08 | 30 | ||
2000-02-18 | 1999-12-31 | -0.26 | -0.26 | 0.0 | 0 | ||
1999-11-01 | 1999-09-30 | -0.22 | -0.24 | -0.02 | 9 |
Biomarin Pharmaceutical Corporate Management
| Laura Woodhead | VP Counsel | Profile | |
| George Davis | Chief VP | Profile | |
| Traci McCarty | Group Relations | Profile | |
| Jonathan Day | Executive Science | Profile | |
| Cristin Hubbard | Executive Officer | Profile | |
| Marni Kottle | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.13 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.